Filing Analysis
Lantern Pharma Inc. filed an 8-K to announce the release of its financial results for the second quarter ended June 30, 2026. The filing includes a press release and a presentation intended for use during a conference call and live webinar.
📋 Key Facts
- Reporting period: Second Quarter ended June 30, 2026.
- Filing date: August 14, 2026.
- The company will host a conference call and live webinar to discuss financial and operating results.
- Exhibits include a press release (99.1) and a presentation (99.2).
Lantern Pharma Inc. announced the establishment of Open-Medicine AI as a separate entity to commercialize its multi-agent AI co-scientist platform for drug development.
🚩 Red Flags
- Spin-off/Separation: While often used to unlock value, the creation of a separate company can sometimes be used to isolate high-risk or capital-intensive assets from the parent company.
📋 Key Facts
- Date of report: August 3, 2026
- Announced the creation of 'Open-Medicine AI' as a standalone company.
- The new entity will focus on commercializing and expanding Lantern's multi-agent AI co-scientist platform.
- Information was released via press release under Item 7.01 (Regulation FD Disclosure).
Lantern Pharma Inc. filed an 8-K to furnish a presentation used on June 1, 2026, regarding the Harmonic™ Phase 2 clinical trial for its product candidate LP-300.
📋 Key Facts
- The filing date is June 1, 2026.
- The company provided a presentation (Exhibit 99.1) concerning the Harmonic™ Phase 2 clinical trial.
- The subject of the trial is the product candidate LP-300.
Lantern Pharma Inc. announced its financial results for the first quarter ended March 31, 2026. The announcement was made via a press release furnished as an exhibit to the filing.
📋 Key Facts
- The report was filed on May 15, 2026, regarding financial results for the quarter ended March 31, 2026.
- The filing was made under Item 2.02 (Results of Operations and Financial Condition).
- The financial information was furnished and not deemed 'filed' for purposes of Section 18 of the Exchange Act.
Lantern Pharma raised $4.4 million through a registered direct offering and concurrent private placement of warrants. Additionally, the company announced plans to spin off its AI platform, withZeta.ai, into an independent business entity to potentially realize separate valuation multiples.
🚩 Red Flags
- 100% warrant coverage (2,135,923 warrants issued alongside 2,135,923 shares/pre-funded warrants) which is highly dilutive.
- Two-year restriction on 'Variable Rate Transactions', which may limit future financing flexibility.
- The offering price of $2.06 and warrant exercise price of $2.27 suggest significant downward pressure on the stock price relative to historical levels.
📋 Key Facts
- Issued 1,454,175 shares of common stock and 681,748 pre-funded warrants at an offering price of $2.06 per unit.
- Concurrent private placement of 2,135,923 purchase warrants with an exercise price of $2.27 per share.
- Total gross proceeds of approximately $4.4 million before fees and expenses.
- Announced the planned creation of an independent entity for the 'withZeta.ai' platform and related technologies.
- Suspended the existing At-The-Market (ATM) sales agreement with ThinkEquity LLC as of May 12, 2026.
- Investors in this round received a right to participate in up to 30% of future equity financings of the AI subsidiary.
Lantern Pharma Inc. conducted a live demonstration and presentation of its 'withZeta.ai' platform, a multi-agentic AI co-scientist designed for rare cancer drug discovery and clinical trial design. The presentation detailed the platform's commercial architecture, revenue strategy, and growth roadmap.
🚩 Red Flags
- The company notes a risk that they may not be able to secure sufficient future funding to support the withZeta.ai platform.
📋 Key Facts
- The demonstration occurred on April 9, 2026, focusing on the withZeta.ai platform.
- The platform is intended to assist in rare cancer drug discovery, development, and clinical trial design.
- The company's near-term revenue strategy for the platform includes software licensing and subscription models.
- A replay of the demonstration was made available via a Zoom recording link.
- The filing includes Exhibit 99.1, which is the presentation used during the demonstration.
Lantern Pharma Inc. announced its financial and operating results for the fiscal year and fourth quarter ended December 31, 2025. The filing includes a press release and a presentation for a scheduled conference call and live webinar to discuss these results.
📋 Key Facts
- Financial results for the fiscal year and fourth quarter ended December 31, 2025, were announced on March 30, 2026.
- The company furnished a press release as Exhibit 99.1 under Item 2.02.
- A presentation for a conference call and live webinar was furnished as Exhibit 99.2 under Item 7.01.
- The filing was signed by David R. Margrave, Chief Financial Officer.
Lantern Pharma Inc. provided a presentation regarding an event held on January 22, 2026, demonstrating the company's initial AI tools and multi-agentic systems focused on rare cancers.
📋 Key Facts
- Event date: January 22, 2026
- Subject matter: Demonstration of initial AI tools and a multi-agentic system for rare cancer research/treatment.
- The presentation is furnished under Item 7.01 (Regulation FD Disclosure) and is not considered 'filed' for liability purposes.
Lantern Pharma Inc. filed an 8-K to announce the release of its third quarter financial results for the period ended September 30, 2025. The filing includes a press release and a presentation intended for use during a scheduled conference call and webinar.
📋 Key Facts
- Company announced Q3 2025 financial results on November 13, 2025.
- Financial results are contained in Exhibit 99.1 (Press Release).
- A presentation for the earnings call is provided in Exhibit 99.2.
- The company is an 'emerging growth company' as defined by the SEC.
Lantern Pharma Inc. held its 2025 Annual Meeting of Stockholders on September 19, 2025. The meeting resulted in the election of six directors and the approval of a one-time stock option repricing.
🚩 Red Flags
- One-time repricing of stock options was approved with significant opposition (nearly 34% of votes cast were 'Against').
📋 Key Facts
- Annual Meeting held on September 19, 2025.
- Six directors elected: Donald Jeff Keyser, Panna Sharma, Vijay Chandru, Maria Maccecchini, Lee T. Schalop, and David S. Silberstein.
- Stockholders approved a one-time repricing of certain stock options under the 2018 Equity Incentive Plan (1,458,333 votes 'For' vs 758,870 'Against').
- Ratification of EisnerAmper LLP as independent registered public accounting firm for fiscal year ending Dec 31, 2025.
Lantern Pharma Inc. filed an 8-K to announce the release of its financial results for the second quarter ended June 30, 2025.
📋 Key Facts
- The company issued a press release on August 13, 2025, regarding Q2 2025 financial results.
- Financial results cover the period ending June 30, 2025.
- The filing includes Exhibit 99.1 containing the press release.
Lantern Pharma Inc. announced the appointment of Lee T. Schalop, M.D. to its Board of Directors and approved an amendment to its By-laws reducing the stockholder meeting quorum requirement from a majority to one-third (33.33%) of outstanding shares.
🚩 Red Flags
- Reduction of quorum requirements can be used to facilitate corporate actions with lower shareholder participation, potentially diluting minority shareholder influence.
📋 Key Facts
- Lee T. Schalop, M.D. appointed to the Board on July 24, 2025.
- Dr. Schalop was a co-founder and former CEO/COO of Oncoceutics, Inc., which was sold to Chimerix Inc. for $450 million.
- By-laws amended to reduce quorum requirement from a majority to one-third (33.33%) of outstanding shares entitled to vote.
- The amendment to Section 2.07 of the By-laws is effective immediately.
Lantern Pharma Inc. entered into an At-The-Market (ATM) sales agreement with ThinkEquity LLC to facilitate the potential sale of up to $15,530,000 in common stock.
🚩 Red Flags
- Potential for immediate equity dilution for existing shareholders via ATM offering.
- ATM offerings are often used by micro-cap biotech companies to fund ongoing operational burn rates.
📋 Key Facts
- Entered into ATM Sales Agreement with ThinkEquity LLC on July 3, 2025.
- Maximum aggregate offering price: $15,530,000.
- Agent (ThinkEquity LLC) will receive a 3.0% commission on gross proceeds.
- Shares to be sold are registered under the Company's existing Form S-3 (effective June 10, 2024).
- The company is not obligated to make any sales under this agreement.
Lantern Pharma Inc. filed an 8-K to announce the release of its financial results and a presentation for the first quarter ended March 31, 2025.
📋 Key Facts
- Company announced Q1 2025 financial results on May 15, 2025.
- The filing includes a press release (Exhibit 99.1) and a presentation for a conference call/webinar (Exhibit 99.2).
- The company is an emerging growth company.
Lantern Pharma Inc. filed an 8-K to announce its financial results for the fiscal year and fourth quarter ended December 31, 2024. The filing includes a press release and a presentation used during a conference call.
📋 Key Facts
- Reported date: March 27, 2025
- Reporting period: Fiscal year and Q4 ended December 31, 2024
- The company is an emerging growth company
- Exhibits include a press release (99.1) and a presentation (99.2)
Lantern Pharma Inc. announced an amendment to the employment agreement for its Chief Scientific Officer, Kishor G. Bhatia, effective January 2025.
🚩 Red Flags
- Reduction in minimum weekly commitment (from unspecified previous level to 24 hours) may indicate a shift in focus or part-time status for the CSO.
📋 Key Facts
- The Board of Directors approved an amendment to Dr. Kishor G. Bhatia's Employment Agreement on January 6, 2025.
- The term of the agreement is extended until January 15, 2026.
- Minimum weekly commitment adjusted to 24 hours per week for scientific and clinical development operations.
- Annual base salary adjusted to $189,600, effective with the first pay period in January 2025.
Lantern Pharma Inc. filed an 8-K to provide a presentation used during its third quarter 2024 earnings conference call and webinar held on November 7, 2024.
📋 Key Facts
- The filing relates to the discussion of financial and operating results for the third quarter ended September 30, 2024.
- A presentation was utilized during a live webinar and conference call on November 7, 2024.
- Exhibit 99.1 contains the specific presentation materials discussed.
Lantern Pharma Inc. filed an 8-K to announce the issuance of its third quarter 2024 financial results for the period ended September 30, 2024.
📋 Key Facts
- The company issued a press release on November 7, 2024, regarding Q3 2024 financial results.
- Financial results cover the quarter ending September 30, 2024.
- The filing is an announcement of earnings rather than the full data set (which is contained in Exhibit 99.1).
Lantern Pharma Inc. filed an 8-K to announce the release of its second quarter 2024 financial results and provide clinical trial updates for its LP-300 product candidate.
📋 Key Facts
- Company will issue a press release regarding Q2 ended June 30, 2024, on August 8, 2024.
- The company is hosting a conference call and live webinar to discuss financial and operating results.
- Management will present information regarding the Harmonic™ Phase 2 clinical trial for product candidate LP-300.
Lantern Pharma Inc. held its 2024 Annual Meeting of Stockholders on June 13, 2024. The meeting resulted in the election of five directors and approval of an amendment to the company's Equity Incentive Plan.
📋 Key Facts
- Held 2024 Annual Meeting of Stockholders on June 13, 2024.
- Five directors elected: Donald Jeff Keyser, Panna Sharma, Vijay Chandru, Maria Maccecchini, and David S. Silberstein.
- Stockholders approved an amendment to the 2018 Equity Incentive Plan to increase available shares by 125,000.
- Ratified the appointment of EisnerAmper LLP as independent registered public accounting firm for fiscal year ending Dec 31, 2024.
Lantern Pharma Inc. announced an amendment to its Bylaws regarding the procedure for determining the authorized number of directors on the Board.
📋 Key Facts
- The Board of Directors approved an amendment to the Company's By-laws effective May 23, 2024.
- The amendment modifies Section 3.02 concerning how the number of directors is fixed.
- Previously, the board size was determined by a majority of total directors assuming no vacancies; the new rule allows the Board to fix the number via simple resolution.
Lantern Pharma Inc. filed an 8-K to announce the release of its financial and operating results for the first quarter ended March 31, 2024.
📋 Key Facts
- The company issued a press release (Exhibit 99.1) regarding Q1 2024 financial results on May 9, 2024.
- A presentation was provided (Exhibit 99.2) for use during a conference call and live webinar to discuss the quarterly results.
Lantern Pharma Inc. filed an 8-K to announce the release of its financial results for the fiscal year and fourth quarter ended December 31, 2023. The filing includes a press release and a presentation intended for use during a conference call and webinar.
📋 Key Facts
- Reporting period: Fiscal year and fourth quarter ended December 31, 2023.
- Filing date: March 18, 2024.
- The company is an emerging growth company.
- Exhibits include a press release (99.1) and a presentation for the earnings call (99.2).